Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Metropolis Healthcare - Acquires Hitech Diagnostics in South India - ICICI Securities

Posted On: 2021-01-19 05:08:59 (Time Zone: Arizona, USA)


Metropolis Healthcare (Metropolis) has announced its acquisition of 100% stake in Dr. SP Ganesan's Hitech Diagnostic Centre (Hitech) in a cash+stock deal. Hitech is a leading player in South India (primarily Chennai and Bengaluru) with a network of 31 labs and 68 collection centers. This acquisition will help Metropolis in strengthening presence in South India, improving B2C contribution as Hitech has higher B2C proportion in revenue and in driving potential cost synergies in coming years. Metropolis will pay a cash consideration of Rs5.1bn and also issue 4,95,000 equity shares for 100% ownership. The acquisition has been valued at 7.4xSales and ~26.5xEV/EBITDA on FY20 basis (assuming issue of shares at CMP). We estimate these valuations to be ~38% lower than Metropolis' existing valuations. Maintain ADD with a revised target price of Rs2,368/share.

- Hitech acquisition to augment presence in South India with higher B2C focus: Hitech is a well-known diagnostics chain in South India, particularly in Chennai, Bengaluru and other cities of Tamil Nadu. Hitech is the 2nd largest player in Chennai after Metropolis and as per the company, this combined entity will be the leading diagnostic player in Chennai. Hitech's infrastructure network includes 31 laboratories, with 3 NABL & ICMR accredited and 68 collection centers. It caters mainly to mid-segment of the market with higher B2C focus which contributes ~65% to total sales for Hitech. This acquisition will be a strategic fit despite some overlap since Metropolis also has a strong presence in the region. Nevertheless, this transaction will help in driving some cost synergies.

- Financial impact: Hitech had revenue of Rs833mn in FY20 with EBITDA margin similar to Metropolis. 9MFY21 revenue is up ~50% aided by COVID-19 related tests with higher EBITDA margin. We assume 40% revenue growth in FY21E and flat FY22 revenue as COVID-19 contribution will decelerate in our view. Hence, this acquisition will result in ~10% increase in revenue and EBITDA of Metropolis in FY22 and FY23. Management expects this deal to be EPS accretive from day 1. We forecast PAT increase of 1.4% in FY22E and 1.3% in FY23E after assuming gross block addition of Rs700mn, intangibles of Rs1.4bn and goodwill increase of Rs4.1bn. The cash consideration of Rs5.1bn will be funded by internal accruals and debt of up to Rs3bn at an interest cost of less than 6%.

- Outlook: We expect Metropolis to outperform industry growth and register revenue, EBITDA and PAT growth at CAGRs of 18.8%, 22.5% and 21.8%, respectively, over FY20-FY23E. Generation of free cashflow worth ~Rs3bn in FY23E would help in retiring debt. Return ratios will remain strong.

- Valuation: We maintain our ADD rating on the stock with DCF-based revised target price of Rs2,368/share (earlier: Rs2,254/share) implying 45.9xFY23E EPS and 28.2xFY23E EV/EBITDA. Key downside risks: Higher-than-expected competition, pricing pressures and regulatory hurdles.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

4th Industrial Conclave - Bullish undertone, favourable valuation - HDFC Securities

Sanofi India - Weak quarter; sequential improvement - ICICI Securities

Sunteck Realty - All eyes on upcoming launches - ICICI Securities

Company Update - Tata Motors - ICICI Direct

Q4CY20 Company Update - Mahindra CIE Automotive - ICICI Direct

Event Update - Hindalco - ICICI Direct

EY report launch at BioAsia 2021 - Moving the needle: Healthcare industry in a post-COVID world

Initiating Coverage - Dalmia Bharat Ltd - HDFC Securities Retail Research Desk

Initiating Coverage - Mastek Ltd - HDFC Securities Retail Research Desk

Hindalco Industries - Status quo maintained - ICICI Securities

Tata Motors - India business scaling in the right direction - ICICI Securities

IPO Review - Heranba Industries Ltd

Company Update - Narayana Hrudayalaya - ICICI Direct

Ambuja Cements - Market share sustenance key for rerating - ICICI Securities

ADD on Astral Poly Technik - An 'astr'onomical growth story - HDFC Securities

FMCG Sector Update Report - Divergence narrows; refocus on core - HDFC Securities

Maintain REDUCE on Jubilant FoodWorks - More legs for growth; reflecting confidence on core - HDFC Securities

Torrent Power - Growth acceleration - ICICI Securities

Mahindra CIE Automotive - CY20 performance closes on a strong note - ICICI Securities

Q3FY21 Company Update - V-Guard Industries - ICICI Direct

Quant Pick - Indus Towers - ICICI Direct

Q4CY20 Result Update - Ambuja Cement - ICICI Direct

Q3FY21 Company Update - Nesco Ltd - ICICI Direct

Maintain BUY on Ambuja Cements - Healthy quarter; multiple triggers ahead - HDFC Securities

Heranba Industries Ltd. - IPO - Sound Financials & Promising Outlook Augur Well

India Equity Strategy Report - Quarterly flipbook: Q3 - upgrades galore! - HDFC Securities

Earnings Wrap Q3FY21: Encouraging quarter, broad based recovery under way!

Shilpa Medicare - USFDA import alert at Jadcherla unit - ICICI Securities

Q3FY21 Company Update - Indian Bank - ICICI Direct

Quant Pick - Torrent Power - ICICI Direct

GE T&D India - Strong cashflow - ICICI Securities

Q3FY21 Result Update - Graphite India - ICICI Direct

Q4CY2020 Result Update - Varun Beverages - ICICI Direct

Q3FY21 Company Update - NBCC Ltd - ICICI Direct

Quant Pick - United Breweries - ICICI Direct

Q4CY2020 Result Update - Nestlé India - ICICI Direct

Q3FY21 Result Update - Time Technoplast - ICICI Direct

Healthy Business Performance Puts ITC Stock Recovery on Track

Gold - Feb 17, 2021 - Reliance Securities

Maintain REDUCE on Nestle India - Steady revenue show; employee cost dents margins - HDFC Securities

Varun Beverages - Q4 CY20 Result and Concall Update - YES Securities

Nestle India - Q4 CY20 Result Update - YES Securities

Reiterate BUY on JMC Projects - Some hits, some misses - HDFC Securities

Varun Beverages - Strong volumes; higher margins - ICICI Securities

Computer Age Management Services - Play on industry AUM growth - ICICI Securities

Nestle India - Just a tad underwhelming (given the high benchmarks expected from Nestle India) - ICICI Securities

NHPC - Earnings robust; projects on track - ICICI Securities

Maintain BUY on ITD Cementation - Gradual recovery shaping up - HDFC Securities

Techno Electric & Engineering - Strong margins, healthy growth outlook - ICICI Securities

Time Technoplast - Outlook upbeat; execution remains key - ICICI Securities



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020